Literature DB >> 23989777

Patient-focused drug development programme takes first steps.

Asher Mullard.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23989777     DOI: 10.1038/nrd4104

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

1.  Increasing patient participation in drug development.

Authors:  Paul Wicks; Maria Lowe; Susan Gabriel; Slaven Sikirica; Rahul Sasane; Stephen Arcona
Journal:  Nat Biotechnol       Date:  2015-02       Impact factor: 54.908

2.  Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.

Authors:  Ilene L Hollin; Holly L Peay; John F P Bridges
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

3.  A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes.

Authors:  Ellen M Janssen; Jodi B Segal; John F P Bridges
Journal:  Patient       Date:  2016-10       Impact factor: 3.883

4.  Identifying the benefits and risks of emerging treatments for idiopathic pulmonary fibrosis: a qualitative study.

Authors:  John F P Bridges; Victoria Federico Paly; Elizabeth Barker; Dolly Kervitsky
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

5.  Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.

Authors:  Eva G Katz; Brett Hauber; Srihari Gopal; Angie Fairchild; Amy Pugh; Rachel B Weinstein; Bennett S Levitan
Journal:  Patient Prefer Adherence       Date:  2016-10-21       Impact factor: 2.711

6.  Research as an event: a novel approach to promote patient-focused drug development.

Authors:  Jui-Hua Tsai; Ellen Janssen; John Fp Bridges
Journal:  Patient Prefer Adherence       Date:  2018-05-03       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.